Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
101 Topics for Clinical Microbiology Laboratory Leaders : Accreditation, Verification, Quality Systems, and More
| 101 Topics for Clinical Microbiology Laboratory Leaders : Accreditation, Verification, Quality Systems, and More |
| Autore | Martin Rebekah M |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Newark : , : ASM Press, , 2025 |
| Descrizione fisica | 1 online resource (256 pages) |
| Disciplina | 579.076 |
| Collana | ASM Bks. |
| Soggetto topico |
Laboratories, Clinical - standards
Microbiological Techniques - standards Accreditation - standards |
| ISBN |
9781683674481
1683674480 9781683674474 1683674472 9781683674467 1683674464 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Dedication Page -- Contents -- Foreword -- Preface -- Acknowledgments -- About the Author -- List of Abbreviations -- Part I Getting Started: Regulatory Oversight and Laboratory Accreditation -- Chapter 1 Clinical Laboratory Improvement Amendments (CLIA) and Regulatory Oversight -- How is "clinical laboratory" defined? -- What is CLIA? -- What is the Code of Federal Regulations (CFR)? -- What roles do the Centers for Medicare and Medicaid Services (CMS), the Centers for Disease Control and Prevention (CDC), and the U.S. Food and Drug Administration (FDA) play in regulating clinical laboratories? -- What is an FDA-cleared or FDA-approved test? -- What is a laboratory developed test (LDT)? -- What does the FDA final rule mean for my laboratory? -- FDA Requirements -- Implementation Stages and Compliance Start Dates -- LDT Categories -- Targeted Enforcement Discretion -- Legal Challenges to the FDA Final Rule -- What is Emergency Use Authorization (EUA)? -- What is test complexity? -- Is there a list of tests categorized by complexity? -- References -- Chapter 2 Clinical Laboratory Improvement Amendments (CLIA) Certificates -- Which laboratories need a CLIA certificate? -- Which laboratories are NOT required to obtain a CLIA certificate? -- What are the types of CLIA certificates? -- What procedures are categorized as provider-performed microscopy (PPM) procedures? -- How does a laboratory obtain a CLIA certificate? -- How many laboratories can be on one CLIA certificate? -- Can one location have multiple CLIA certificates? -- How many CLIA certificates can one laboratory director have? -- How long is a CLIA certificate effective, and how does a laboratory renew a CLIA certificate? -- What are the laboratory specialties and subspecialties? -- Which states have CLIA-exempt laboratory programs?.
When can a laboratory begin testing? -- Who should be notified if there are changes in the laboratory, and when? -- What happens if a laboratory is out of compliance with CLIA requirements? -- References -- Chapter 3 Waived Testing -- What are waived tests? -- Is there a list of tests that are waived? -- Is my laboratory subject to inspection if we perform waived testing? -- What are the personnel qualifications for performing waived testing in clinical laboratories? -- Are there compliance exemptions for laboratories performing waived testing? -- References -- Chapter 4 Laboratory Accreditation -- What is laboratory accreditation? -- What are the current CMS-approved accrediting agencies? -- How can my laboratory become accredited? -- How does my laboratory maintain accreditation? -- What happens during a laboratory inspection? -- How does a laboratory respond when cited for deficiencies? -- How is laboratory noncompliance addressed by CMS? -- Can I become a laboratory inspector? -- What is "ISO certification/accreditation" and does my laboratory need it? -- I need some help with terms! -- References -- Part II Going Live: Verification and Validation of Test Systems -- Chapter 5 Verification and Validation -- What are verification and validation? -- When should a laboratory perform a verification or validation study? -- What is a test system? -- What counts as a modification to a test system? -- Who is responsible for designing and implementing a verification or validation study? -- Can the company who made the instrument perform the verification study? -- What performance characteristics should be assessed for a verification study? -- What performance characteristics should be assessed for a validation study? -- Is verification/validation necessary for point of care and other CLIA-waived assays?. My laboratory is moving an instrument. Is a verification/validation necessary? -- My laboratory has five of the same instruments running the same assay. Do we have to run a verification/validation on each instrument? -- My laboratory has multiple high-complexity laboratories across the health system that run the same assays on the same platform. Does a verification/validation need to be performed at each location? -- My laboratory stopped running a particular assay. Is verification/validation necessary to resume testing with this assay? -- My laboratory is running a test under Emergency Use Authorization (EUA). Is verification/validation required? -- Which laboratory personnel are involved in a verification/validation study? -- References -- Chapter 6 Performance Characteristic: Precision -- What is precision? -- How many and what types of samples should be used to assess precision? -- How does a laboratory assess precision for qualitative assays? -- How does a laboratory assess precision for quantitative assays? -- What calculations should be used for precision? -- How can precision be assessed for matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) identification systems? -- How can precision be assessed for antimicrobial susceptibility test (AST) systems? -- How can precision be assessed for multiplex molecular systems? -- References -- Chapter 7 Performance Characteristic: Accuracy/Agreement -- What is accuracy? -- How many and what types of samples should be used to assess accuracy? -- What calculations should be used for accuracy? -- What calculations should be used for agreement? -- How does disease prevalence affect test performance? -- How can accuracy be assessed for matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) identification systems?. How can accuracy be assessed for antimicrobial susceptibility test (AST) systems? -- How can accuracy be assessed for multiplex molecular systems? -- References -- Chapter 8 Performance Characteristic: Reportable Range -- What is reportable range? -- How many and what types of samples should be used to assess reportable range? -- How does a laboratory assess reportable range for quantitative assays? -- How does a laboratory assess reportable range for qualitative assays? -- How can reportable range be assessed for matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) identification systems? -- How can reportable range be assessed for antimicrobial susceptibility test (AST) systems? -- How can reportable range be assessed for multiplex molecular systems? -- References -- Chapter 9 Performance Characteristic: Reference Interval -- What is a reference interval? -- How many and what types of samples should be used to assess the reference interval? -- How does a laboratory assess the reference interval? -- What calculations should be used for reference interval? -- How can the reference interval be assessed for matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) identification systems? -- How can the reference interval be assessed for antimicrobial susceptibility test (AST) systems? -- How can the reference interval be assessed for multiplex molecular systems? -- References -- Chapter 10 Performance Characteristic: Analytical Sensitivity -- What is analytical sensitivity? -- How many and what types of samples should be used to assess analytical sensitivity? -- How does a laboratory assess analytical sensitivity? -- What calculations should be used for analytical sensitivity? -- How can analytical sensitivity be assessed for matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) identification systems?. How can analytical sensitivity be assessed for antimicrobial susceptibility test (AST) systems? -- How can analytical sensitivity be assessed for multiplex molecular systems? -- References -- Chapter 11 Performance Characteristic: Analytical Specificity -- What is analytical specificity? -- How many and what types of samples should be used to assess analytical specificity? -- How does a laboratory assess analytical specificity? -- What should we do if cross-reactivity or interfering substances are identified? -- How can analytical specificity be assessed for matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) identification systems? -- How can analytical specificity be assessed for antimicrobial susceptibility test (AST) systems? -- How can analytical specificity be assessed for multiplex molecular systems? -- References -- Chapter 12 Additional Performance Characteristics -- What additional performance characteristics could be considered, and how are they assessed? -- References -- Chapter 13 Unacceptable Results and Resolution -- What should we do if there are significant discrepancies between our new assay and the comparator assay? (Accuracy) -- We are using a less sensitive method as our comparator method, and our new test is showing poor agreement and increased "false positives." What should we do? (Accuracy) -- Our assay shows significant cross-reactivity with a particular organism. What should we do? (Analytical specificity) -- References -- Chapter 14 Documentation for Verification and Validation Studies -- What documentation is necessary for a verification or validation study? -- What should be included in a verification/validation plan? -- What should be included in a verification/validation summary? -- How long is the laboratory required to keep verification/validation documentation?. What do I do if my laboratory's legacy assays do not have verification/validation documentation?. |
| Record Nr. | UNINA-9910984595603321 |
Martin Rebekah M
|
||
| Newark : , : ASM Press, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Accessing uncultivated microorganisms : from the environment to organisms and genomes and back / edited by Karsten Zengler
| Accessing uncultivated microorganisms : from the environment to organisms and genomes and back / edited by Karsten Zengler |
| Pubbl/distr/stampa | Washington, : ASM Press, c2008 |
| Descrizione fisica | XII, 308 p. : ill. ; 26 cm |
| Disciplina |
576.15
579.17 |
| Soggetto non controllato | Ecologia dei microrganismi |
| ISBN | 978-1-55581-406-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-990008809860403321 |
| Washington, : ASM Press, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antibiotics : challenges, mechanisms, opportunities / / by Christopher Walsh and Timothy Wencewicz
| Antibiotics : challenges, mechanisms, opportunities / / by Christopher Walsh and Timothy Wencewicz |
| Autore | Walsh Christopher |
| Pubbl/distr/stampa | Washington, District of Columbia : , : ASM Press, , 2016 |
| Descrizione fisica | 1 online resource (490 p.) |
| Disciplina | 615.329 |
| Soggetto topico |
Antibiotics
Drug resistance in microorganisms |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-68367-331-X
1-55581-931-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Preface; Section I: Challenges for Antibiotics; 1 Antibiotics: Initial Concepts and Considerations; Waves of Resistant Bacterial Infections; Differential Susceptibility to Antibiotics; Empiric Therapy and Broad-spectrum Antibiotics; Antibiotic Flow Chart; Recent Approvals and the Current Antibiotic Pipeline; Recognition of Pressing Need for New Antibiotics: "The End is Near" Scenarios; Approach and Organization of This Volume; 2 Major Classes of Antibiotics and Their Modes of Action; Antibiotics Versus Antimicrobials: Antibacterial Versus Antifungal Versus Antiprotozoal Agents
What Bacteria to TargetHow to Test for Antibiotic Activity; How to Find Antibiotics; A Golden Age of Antibiotic Medicinal Chemistry; What is the Capacity for Microbes to Make Antibiotics?; Target Classes Identified from the Major Antibiotic Groups; A Common Pathway for Bactericidal Antibiotics?; Section II: Mechanisms: Antibiotic Action by Bacterial Target Class; 3 Assembly of the Peptidoglycan Layer of Bacterial Cell Walls; Introduction; Nature of the PG Layer of the Cell Envelope; Biosynthesis and Insertion of PG Monomer Units PG Assembly: Phase 1 in the Cytoplasm-Generation of UDP-Muramyl PentapeptidePG Assembly: Phase 2 at the Inner Face of the Cytoplasmic Membrane-the C55 Bactoprenol Lipid Carrier; PG Assembly: Phase III-Chain Extension and Cross-Linking at the Outer Face of the Cytoplasmic Membrane; Summary; 4 Antibiotics That Block Peptidoglycan Assembly and Integrity; Introduction; PG Transpeptidase Inhibition: β-Lactam Antibiotics; Four Subclasses of Antibiotics: Penams, Cephems, Carbapenems, and Monobactams; Mechanisms of Action of Lactam Antibiotics: Acylation of Transpeptidases; The Families of PBPs Acyl Enzyme Lifetimes Are CrucialPBP Inventories; Many Side Chain Variants in Semisynthetic β-Lactam Antibiotics; The Future for β-Lactam Antibiotics?; Moenomycin: Inhibition of PG Transglycosylases; Antibiotics That Act as Substrate Binders and Sequestrants in the Bactoprenol Metabolic Cycle; MraY and Peptidyl Nucleoside Antibiotics; How Do Bacteria Respond to Categories of Antibiotics That Target the Cell Wall?; 5 Antibiotics That Disrupt Membrane Integrity; Introduction; Antimicrobial Peptides and Defensins; Lantibiotic Peptides Calprotectin, an Antimicrobial Protein That Complexes Mn(II) and Fe(II)Bacterial Lipopeptides; Surfactin; Daptomycin Disrupts Bacterial Membrane Integrity; Polymyxin: an Old Antibiotic Revisited; Dual Mechanisms for SecondGeneration Lipoglycopeptide Antibiotics; 6 Antibiotics That Block Protein Synthesis; Overview of Bacterial Protein Synthesis; Antibiotics That Target Aminoacyl-tRNA Synthetases; Antibiotics That Target the Bacterial Ribosome; EF-Tu: an Aminoacyl-tRNA Chaperone as Antibiotic Target; 7 Antibiotics That Target DNA and RNA Information Transfer Antibiotics Directed against Type II Topoisomerases |
| Record Nr. | UNINA-9910555016503321 |
|
Walsh Christopher
|
||
| Washington, District of Columbia : , : ASM Press, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antibiotics : challenges, mechanisms, opportunities / / by Christopher Walsh and Timothy Wencewicz
| Antibiotics : challenges, mechanisms, opportunities / / by Christopher Walsh and Timothy Wencewicz |
| Autore | Walsh Christopher |
| Pubbl/distr/stampa | Washington, District of Columbia : , : ASM Press, , 2016 |
| Descrizione fisica | 1 online resource (490 p.) |
| Disciplina | 615.329 |
| Soggetto topico |
Antibiotics
Drug resistance in microorganisms |
| ISBN |
1-68367-331-X
1-55581-931-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Preface; Section I: Challenges for Antibiotics; 1 Antibiotics: Initial Concepts and Considerations; Waves of Resistant Bacterial Infections; Differential Susceptibility to Antibiotics; Empiric Therapy and Broad-spectrum Antibiotics; Antibiotic Flow Chart; Recent Approvals and the Current Antibiotic Pipeline; Recognition of Pressing Need for New Antibiotics: "The End is Near" Scenarios; Approach and Organization of This Volume; 2 Major Classes of Antibiotics and Their Modes of Action; Antibiotics Versus Antimicrobials: Antibacterial Versus Antifungal Versus Antiprotozoal Agents
What Bacteria to TargetHow to Test for Antibiotic Activity; How to Find Antibiotics; A Golden Age of Antibiotic Medicinal Chemistry; What is the Capacity for Microbes to Make Antibiotics?; Target Classes Identified from the Major Antibiotic Groups; A Common Pathway for Bactericidal Antibiotics?; Section II: Mechanisms: Antibiotic Action by Bacterial Target Class; 3 Assembly of the Peptidoglycan Layer of Bacterial Cell Walls; Introduction; Nature of the PG Layer of the Cell Envelope; Biosynthesis and Insertion of PG Monomer Units PG Assembly: Phase 1 in the Cytoplasm-Generation of UDP-Muramyl PentapeptidePG Assembly: Phase 2 at the Inner Face of the Cytoplasmic Membrane-the C55 Bactoprenol Lipid Carrier; PG Assembly: Phase III-Chain Extension and Cross-Linking at the Outer Face of the Cytoplasmic Membrane; Summary; 4 Antibiotics That Block Peptidoglycan Assembly and Integrity; Introduction; PG Transpeptidase Inhibition: β-Lactam Antibiotics; Four Subclasses of Antibiotics: Penams, Cephems, Carbapenems, and Monobactams; Mechanisms of Action of Lactam Antibiotics: Acylation of Transpeptidases; The Families of PBPs Acyl Enzyme Lifetimes Are CrucialPBP Inventories; Many Side Chain Variants in Semisynthetic β-Lactam Antibiotics; The Future for β-Lactam Antibiotics?; Moenomycin: Inhibition of PG Transglycosylases; Antibiotics That Act as Substrate Binders and Sequestrants in the Bactoprenol Metabolic Cycle; MraY and Peptidyl Nucleoside Antibiotics; How Do Bacteria Respond to Categories of Antibiotics That Target the Cell Wall?; 5 Antibiotics That Disrupt Membrane Integrity; Introduction; Antimicrobial Peptides and Defensins; Lantibiotic Peptides Calprotectin, an Antimicrobial Protein That Complexes Mn(II) and Fe(II)Bacterial Lipopeptides; Surfactin; Daptomycin Disrupts Bacterial Membrane Integrity; Polymyxin: an Old Antibiotic Revisited; Dual Mechanisms for SecondGeneration Lipoglycopeptide Antibiotics; 6 Antibiotics That Block Protein Synthesis; Overview of Bacterial Protein Synthesis; Antibiotics That Target Aminoacyl-tRNA Synthetases; Antibiotics That Target the Bacterial Ribosome; EF-Tu: an Aminoacyl-tRNA Chaperone as Antibiotic Target; 7 Antibiotics That Target DNA and RNA Information Transfer Antibiotics Directed against Type II Topoisomerases |
| Record Nr. | UNINA-9910831000803321 |
|
Walsh Christopher
|
||
| Washington, District of Columbia : , : ASM Press, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antibodies for infectious diseases / / edited by James E. Crowe, Jr., Diana Boraschi and Rino Rappuoli
| Antibodies for infectious diseases / / edited by James E. Crowe, Jr., Diana Boraschi and Rino Rappuoli |
| Pubbl/distr/stampa | Washington, District of Columbia : , : ASM Press, , 2015 |
| Descrizione fisica | 1 online resource (476 p.) |
| Disciplina | 616.0798 |
| Soggetto topico |
Immunoglobulins
Communicable diseases - Immunological aspects |
| ISBN |
1-68367-340-9
1-68367-098-1 1-55581-741-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
""Cover ""; ""Half Title ""; ""Title Page ""; ""Copyright ""; ""Contents ""; ""Contr ibutors ""; ""Preface ""; ""INTRODUCTION""; ""Chapter 1: History and Practice: Antibodies in Infectious Diseases""; ""HISTORICAL PERSPECTIVE""; ""INTRODUCTION TO ANTIBODIES""; ""METHODS AND PLATFORMS FOR GENERATING ANTIBODIES""; ""STRATEGIC CONSIDERATIONS IN DEVELOPING ANTIBODY-BASED THERAPIES FOR INFECTIOUS DISEASES""; ""EXAMPLES OF ANTIBODIES THAT ARE OR WERE IN DEVELOPMENT FOR INFECTIOUS DISEASES""; ""FUTURE PERSPECTIVES FOR ANTIBODY TREATMENTS IN INFECTIOUS DISEASES""; ""ACKNOWLEDGMENT""; ""CITATION""
""REFERENCES""""GENERAL FEATURES OF IMMUNOGLOBULINS""; ""Chapter 2: Functions of Antibodies""; ""INTRODUCTION""; ""ANTIBODY FUNCTIONS INDEPENDENT OF EFFECTOR CELLS OR EFFECTOR MOLECULES""; ""INHIBITION OF LATER STEPS""; ""ANTIBODY FUNCTIONS DEPENDENT ON COMPLEMENT""; ""ANTIBODY FUNCTIONS DEPENDENT ON Fc-Fc RECEPTOR INTERACTIONS""; ""OTHER ANTIBODY FUNCTIONS""; ""CONCLUSIONS""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES""; ""Chapter 3: Antibody Structure""; ""BASICS OF ANTIBODY STRUCTURE""; ""CDR H3: SIZE AND SUBTERFUGE""; ""HEAVY CHAIN DOMINATION AND FRAMEWORK CONTACTS"" ""DISULFIDES IN THE CDRs""""SELF-CARBOHYDRATE RECOGNITION: PENETRATING THE GLYCAN SHIELD""; ""UNUSUAL INDELS""; ""MECHANISMS OF ANTIBODY NEUTRALIZATION""; ""SUMMARY""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 4: The Role of Complement in Antibody Therapy for Infectious Diseases""; ""INTRODUCTION""; ""COMPLEMENT ACTIVATION""; ""Ab-MEDIATED COMPLEMENT ACTIVATION""; ""EFFECTOR RESPONSES AND THEIR ROLE IN MAb TREATMENTS""; ""MANIPULATING Ab-MEDIATED COMPLEMENT RESPONSES""; ""COMPLEMENT EVASIVE PROPERTIES OF PATHOGENS""; ""CONCLUSIONS AND FUTURE PERSPECTIVE"" ""ACKNOWLEDGMENTS""""CITATION""; ""REFERENCES""; ""Chapter 5: Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment""; ""IMMUNOLOGICAL MECHANISMS OF ALLERGIC DISEASES AND THE ROLE OF IgE ANTIBODIES""; ""IgE ANTIBODIES IN INFECTIOUS DISEASES""; ""ANTIBODIES IN THE TREATMENT OF ALLERGIES""; ""THE OPPOSITE SIDE OF THE COIN: HARNESSING THE ALLERGIC RESPONSE AGAINST CANCER AND THE EMERGENCE OF ANTIBODIES OF THE IgE CLASS FOR CANCER THERAPY""; ""CONCLUDING REMARKS AND FUTURE ROLES OF ANTIBODIES IN THERAPY""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES"" ""ANTIBODY DISCOVERY APPROACHES""""Chapter 6: Phage and Yeast Display""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING PHAGE DISPLAY TECHNOLOGY""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING YEAST DISPLAY TECHNOLOGY""; ""CONCLUSIONS""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 7: Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells""; ""MANY WAYS TO MAKE HUMAN MONOCLONAL ANTIBODIES""; ""EFFICIENT IMMORTALIZATION OF MEMORY B CELLS BY USING EBV AND CpG"" ""LONG-TERM CULTURE OF SINGLE PLASMA CELLS AND THEIR INTERROGATION USING MULTIPLE ASSAYS"" |
| Record Nr. | UNINA-9910555131903321 |
| Washington, District of Columbia : , : ASM Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antibodies for infectious diseases / / edited by James E. Crowe, Jr., Diana Boraschi and Rino Rappuoli
| Antibodies for infectious diseases / / edited by James E. Crowe, Jr., Diana Boraschi and Rino Rappuoli |
| Pubbl/distr/stampa | Washington, District of Columbia : , : ASM Press, , 2015 |
| Descrizione fisica | 1 online resource (476 p.) |
| Disciplina | 616.0798 |
| Soggetto topico |
Immunoglobulins
Communicable diseases - Immunological aspects |
| ISBN |
1-68367-340-9
1-68367-098-1 1-55581-741-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
""Cover ""; ""Half Title ""; ""Title Page ""; ""Copyright ""; ""Contents ""; ""Contr ibutors ""; ""Preface ""; ""INTRODUCTION""; ""Chapter 1: History and Practice: Antibodies in Infectious Diseases""; ""HISTORICAL PERSPECTIVE""; ""INTRODUCTION TO ANTIBODIES""; ""METHODS AND PLATFORMS FOR GENERATING ANTIBODIES""; ""STRATEGIC CONSIDERATIONS IN DEVELOPING ANTIBODY-BASED THERAPIES FOR INFECTIOUS DISEASES""; ""EXAMPLES OF ANTIBODIES THAT ARE OR WERE IN DEVELOPMENT FOR INFECTIOUS DISEASES""; ""FUTURE PERSPECTIVES FOR ANTIBODY TREATMENTS IN INFECTIOUS DISEASES""; ""ACKNOWLEDGMENT""; ""CITATION""
""REFERENCES""""GENERAL FEATURES OF IMMUNOGLOBULINS""; ""Chapter 2: Functions of Antibodies""; ""INTRODUCTION""; ""ANTIBODY FUNCTIONS INDEPENDENT OF EFFECTOR CELLS OR EFFECTOR MOLECULES""; ""INHIBITION OF LATER STEPS""; ""ANTIBODY FUNCTIONS DEPENDENT ON COMPLEMENT""; ""ANTIBODY FUNCTIONS DEPENDENT ON Fc-Fc RECEPTOR INTERACTIONS""; ""OTHER ANTIBODY FUNCTIONS""; ""CONCLUSIONS""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES""; ""Chapter 3: Antibody Structure""; ""BASICS OF ANTIBODY STRUCTURE""; ""CDR H3: SIZE AND SUBTERFUGE""; ""HEAVY CHAIN DOMINATION AND FRAMEWORK CONTACTS"" ""DISULFIDES IN THE CDRs""""SELF-CARBOHYDRATE RECOGNITION: PENETRATING THE GLYCAN SHIELD""; ""UNUSUAL INDELS""; ""MECHANISMS OF ANTIBODY NEUTRALIZATION""; ""SUMMARY""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 4: The Role of Complement in Antibody Therapy for Infectious Diseases""; ""INTRODUCTION""; ""COMPLEMENT ACTIVATION""; ""Ab-MEDIATED COMPLEMENT ACTIVATION""; ""EFFECTOR RESPONSES AND THEIR ROLE IN MAb TREATMENTS""; ""MANIPULATING Ab-MEDIATED COMPLEMENT RESPONSES""; ""COMPLEMENT EVASIVE PROPERTIES OF PATHOGENS""; ""CONCLUSIONS AND FUTURE PERSPECTIVE"" ""ACKNOWLEDGMENTS""""CITATION""; ""REFERENCES""; ""Chapter 5: Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment""; ""IMMUNOLOGICAL MECHANISMS OF ALLERGIC DISEASES AND THE ROLE OF IgE ANTIBODIES""; ""IgE ANTIBODIES IN INFECTIOUS DISEASES""; ""ANTIBODIES IN THE TREATMENT OF ALLERGIES""; ""THE OPPOSITE SIDE OF THE COIN: HARNESSING THE ALLERGIC RESPONSE AGAINST CANCER AND THE EMERGENCE OF ANTIBODIES OF THE IgE CLASS FOR CANCER THERAPY""; ""CONCLUDING REMARKS AND FUTURE ROLES OF ANTIBODIES IN THERAPY""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES"" ""ANTIBODY DISCOVERY APPROACHES""""Chapter 6: Phage and Yeast Display""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING PHAGE DISPLAY TECHNOLOGY""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING YEAST DISPLAY TECHNOLOGY""; ""CONCLUSIONS""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 7: Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells""; ""MANY WAYS TO MAKE HUMAN MONOCLONAL ANTIBODIES""; ""EFFICIENT IMMORTALIZATION OF MEMORY B CELLS BY USING EBV AND CpG"" ""LONG-TERM CULTURE OF SINGLE PLASMA CELLS AND THEIR INTERROGATION USING MULTIPLE ASSAYS"" |
| Record Nr. | UNINA-9910830911403321 |
| Washington, District of Columbia : , : ASM Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antimicrobial agents : antibacterials and antifungals / edited by André Bryskier
| Antimicrobial agents : antibacterials and antifungals / edited by André Bryskier |
| Pubbl/distr/stampa | Washington : ASM Press, 2005 |
| Descrizione fisica | XXX, 1426 p. : ill. ; 29 cm |
| Disciplina | 615.321 |
| Soggetto non controllato |
Piante medicinali
Farmacognosia |
| ISBN |
978-1-55581-237-9
1-55581-237-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-990009098970403321 |
| Washington : ASM Press, 2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antimicrobial resistance in bacteria from livestock and companion animals / / editors, Stefan Schwarz, Lina Maria Cavaco, Jianzhong Shen ; with Frank Møller Aarestrup
| Antimicrobial resistance in bacteria from livestock and companion animals / / editors, Stefan Schwarz, Lina Maria Cavaco, Jianzhong Shen ; with Frank Møller Aarestrup |
| Pubbl/distr/stampa | Washington, District of Columbia : , : ASM Press, , [2018] |
| Descrizione fisica | 1 online resource (746 pages) |
| Disciplina | 616.9041 |
| Soggetto topico |
Drug resistance in microorganisms
Antibiotics in veterinary medicine |
| ISBN |
1-68367-295-X
1-68367-052-3 1-55581-980-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910555132703321 |
| Washington, District of Columbia : , : ASM Press, , [2018] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiretroviral therapy / edited by Erik D.A. De Clercq
| Antiretroviral therapy / edited by Erik D.A. De Clercq |
| Pubbl/distr/stampa | Washington : ASM Press, c2001 |
| Descrizione fisica | x, 359 p. : ill. ; 26 cm |
| Disciplina | 616.97 |
| Soggetto non controllato |
Biochimica
Scienze mediche - malattie sistema immunitario |
| ISBN | 1-55581-156-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-990001494270403321 |
| Washington : ASM Press, c2001 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antisepsis, disinfection, and sterilization : types, action, and resistance / / Gerald E. McDonnell
| Antisepsis, disinfection, and sterilization : types, action, and resistance / / Gerald E. McDonnell |
| Autore | McDonnell Gerald E. |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | Washington, District of Columbia : , : ASM Press, , 2017 |
| Descrizione fisica | 1 online resource (410 pages) : illustrations (some color) |
| Disciplina | 614.4/8 |
| Soggetto topico |
Sterilization
Asepsis and antisepsis Disinfection and disinfectants |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-68367-307-7
1-68367-085-X 1-5231-1259-X 1-55581-968-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910555263803321 |
|
McDonnell Gerald E.
|
||
| Washington, District of Columbia : , : ASM Press, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pubbl/distr/stampa
-
ASM Press
(282)
- Wiley (9)
- CRC Press (2)
- John Wiley & Sons, Inc (1)